Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for UP421 in Type 1 diabetes. The expected timing is based on the latest available company guidance and may change.
6/23/25- Reported six-month follow-up results at ADA '25. 11/06/25:- NEJM published positive 12-week UP421 IST results; additional longer-term follow-up data expected. 03/03/26:- 12-month UP421 IST results show persistent C-peptide, graft visibility on PET-MRI, and no safety concerns. 03/13/26:- 14-month UP421 follow-up showed persistent C-peptide and no safety issues; data presented at ATTD. 05/11/26:- Fourteen-month IST data show persistent C-peptide, PET-MRI graft visibility, and no safety concerns. 07/01/26:- Present first-in-human UP421 clinical data at EASD 2026 on October 2, 2026. 08/10/26:- NEJM published 14-month UP421 data; EASD 2026 presentation remains October 2, 2026.
Verification
Confirm timing and program details against the company announcement or filing.